The Safety and Utility of Skin Testing With Xolair (Omalizumab) and Placebo Omalizumab (Formulation Excipients).

Trial Profile

The Safety and Utility of Skin Testing With Xolair (Omalizumab) and Placebo Omalizumab (Formulation Excipients).

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 11 Feb 2011 Actual end date (March 2009) added as reported by ClinicalTrials.gov.
    • 11 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top